miR-192-5p在恶性肿瘤中作用机制的研究进展

doi:10.11904/j.issn.1002-3070.2023.05.009

实用肿瘤学杂志 ›› 2023, Vol. 37 ›› Issue (5): 439-442.doi: 10.11904/j.issn.1002-3070.2023.05.009

miR-192-5p在恶性肿瘤中作用机制的研究进展

刘远霖¹ 综述, 冯立² 审校

1.内蒙古医科大学(内蒙古 010100);
2.北京大学肿瘤医院内蒙古医院(内蒙古医科大学附属肿瘤医院;内蒙古自治区肿瘤医院)

收稿日期:2023-05-28 修回日期:2023-09-30 出版日期:2023-10-28 发布日期:2024-03-18
通讯作者: 冯立,E-mail:66552483@qq.com
作者简介:刘远霖,男,(1995-),硕士研究生,从事胃肠肿瘤相关的研究。
基金资助:
内蒙古自治区卫生健康科技计划项目(编号:202202222)

Research progress in the mechanism of miR-192-5p in malignant tumors

LIU Yuanlin¹, FENG Li²

1. Inner Mongolia Medical University,Mongolia 010100,China;
2. Peking University Cancer Hospital(Inner Mongolia Campus)/Affiliated Cancer Hospital of Inner Mongolia Medical University/Inner Mongolia Autonomous Region Cancer Hospital

Received:2023-05-28 Revised:2023-09-30 Online:2023-10-28 Published:2024-03-18

摘要/Abstract

摘要： 恶性肿瘤是威胁人类健康的常见疾病,其治疗也是加重社会经济负担的主要因素之一。恶性肿瘤患者的死亡率高,预后极差。因此,如何提高恶性肿瘤患者的生存率、改善预后至关重要。miRNA是一类小的非编码RNA,通过参与基因表达的转录后调控,在肿瘤细胞的增殖、分化、迁移和凋亡等过程中发挥重要作用。近年来,人们逐渐开始研究miR-192-5p在恶性肿瘤中的表达及作用,本文将对miR-192-5p在不同恶性肿瘤中作用机制的研究进展进行综述。

关键词: miR-192-5p, 恶性肿瘤, 作用机制

Abstract: Malignant tumors is one of the main threats to human health,and their treatment is also one of the main factors that increase the socio-economic burden.Patients with malignant tumors have a high mortality and extremely poor prognosis.Therefore,it is crucial to improve the survival rate and prognosis of patients with malignant tumors.miRNAs are a class of small non-coding RNAs,which play an important role in the proliferation,differentiation,migration,and apoptosis of tumor cells by participating in the post-transcriptional regulation of gene expression.In recent years,researchers have gradually begun to study the expression and role of miR-192-5p in malignant tumors.This paper will review the research progress of miR-192-5p mechanism in different malignant tumors.

Key words: miR-192-5p, Malignant tumors, Mechanism of action

中图分类号:

刘远霖, 冯立. miR-192-5p在恶性肿瘤中作用机制的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 439-442.

LIU Yuanlin, FENG Li. Research progress in the mechanism of miR-192-5p in malignant tumors[J]. Journal of Practical Oncology, 2023, 37(5): 439-442.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.05.009

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I5/439

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Hill M,Tran N.miRNA interplay:mechanisms and consequences in cancer[J].Dis Model Mech,2021,14(4):047662.
3 Schmidt MF.Drug target miRNAs:chances and challenges[J].Trends Biotechnol,2014,32(11):578-585.
4 陈灿,张艳玲,刘小庆,等.miR-182对直肠癌细胞增殖、侵袭及Foxo3a/Wnt/β-catenin通路的调节作用[J].实用肿瘤学杂志,2020,34(4):328-333.
5 Kozomara A,Birgaoanu M,Griffiths-Jones S.miRBase:from microRNA sequences to function[J].Nucleic Acids Res,2019,47(1):155-162.
6 Saliminejad K,Khorram KH,Soleymani FS,et al.An overview of microRNAs:Biology,functions,therapeutics,and analysis methods[J].J Cell Physiol,2019,234(5):5451-5465.
7 Correia DSM,Gjorgjieva M,Dolicka D,et al.Deciphering miRNAs'Action through miRNA Editing[J].Int J Mol Sci,2019,20(24):6249.
8 Xiong J,Xing S,Dong Z,et al.STK31 regulates the proliferation and cell cycle of lung cancer cells via the Wnt/beta-catenin pathway and feedback regulation by c-myc[J].Oncol Rep,2020,43(2):395-404.
9 Pan Y,Sun Y,Liu Z,et al.miR-192-5p upregulation mediates the suppression of curcumin in human NSCLC cell proliferation,migration and invasion by targeting c-Myc and inactivating the Wnt/beta-catenin signaling pathway[J].Mol Med Rep,2020,22(2):1594-1604.
10 Liu K,Xu SH,Chen Z,et al.TRPM7 overexpression enhances the cancer stem cell-like and metastatic phenotypes of lung cancer through modulation of the Hsp90alpha/uPA/MMP2 signaling pathway[J].BMC Cancer,2018,18(1):1167.
11 Liu L,Wu N,Wang Y,et al.TRPM7 promotes the epithelial-mesenchymal transition in ovarian cancer through the calcium-related PI3K/AKT oncogenic signaling[J].J Exp Clin Cancer Res,2019,38(1):106.
12 Dong RF,Zhuang YJ,Wang Y,et al.Tumor suppressor miR-192-5p targets TRPM7 and inhibits proliferation and invasion in cervical cancer[J].Kaohsiung J Med Sci,2021,37(8):699-708.
13 Wang H,Hu Q,Tong Y,et al.LncRNA SOX2-OT regulates miR-192-5p/RAB2A axis and ERK pathway to promote glioblastoma cell growth[J].Cell Cycle,2021,20(19):2010-2020.
14 Zanotelli MR,Zhang J,Reinhart-King CA.Mechanoresponsive metabolism in cancer cell migration and metastasis[J].Cell Metab,2021,33(7):1307-1321.
15 Fu S,Ma C,Tang X,et al.MiR-192-5p inhibits proliferation,migration,and invasion in papillary thyroid carcinoma cells by regulation of SH3RF3[J].Biosci Rep,2021,41(9):20210342.
16 Zhang X,Peng Y,Huang Y,et al.SMG-1 inhibition by miR-192/-215 causes epithelial-mesenchymal transition in gastric carcinogenesis via activation of Wnt signaling[J].Cancer Med,2018,7(1):146-156.
17 Pastushenko I,Blanpain C.EMT transition states during tumor progression and metastasis[J].Trends Cell Biol,2019,29(3):212-226.
18 Flammang I,Reese M,Yang Z,et al.Tumor-suppressive miR-192-5p has prognostic value in pancreatic ductal adenocarcinoma[J].Cancers(Basel),2020,12(6):1693.
19 Yang J,Hou G,Chen H,et al.Circ_0000189 promotes the malignancy of glioma cells via regulating miR-192-5p-ZEB2 Axis[J].Oxid Med Cell Longev,2022,2022:2521951.
20 Xie D,Yin D,Tong X,et al.Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways[J].Cancer Res,2004,64(6):1987-1996.
21 Yin S,Jin W,Qiu Y,et al.Solamargine induces hepatocellular carcinoma cell apoptosis and autophagy via inhibiting LIF/miR-192-5p/CYR61/Akt signaling pathways and eliciting immunostimulatory tumor microenvironment[J].J Hematol Oncol,2022,15(1):32.
22 Chen ZJ,Yan YJ,Shen H,et al.miR-192 is overexpressed and promotes cell proliferation in prostate cancer[J].Med Princ Pract,2019,28(2):124-132.
23 Park MN,Park H,Rahman MA,et al.BK002 Induces miR-192-5p-mediated apoptosis in castration-resistant prostate cancer cells via modulation of PI3K/CHOP[J].Front Oncol,2022,12:791365.
24 Abbas R,Larisch S.Targeting XIAP for promoting cancer cell death-the story of ARTS and SMAC[J].Cells,2020,9(3):663.
25 Tu H,Costa M.XIAP's Profile in human cancer[J].Biomolecules,2020,10(11):1493.
26 Ye M,Zhang J,Zhang J,et al.Curcumin promotes apoptosis by activating the p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer[J].Cancer Lett,2015,357(1):196-205.
27 Bilotta MT,Antignani A,Fitzgerald DJ.Managing the TME to improve the efficacy of cancer therapy[J].Front Immunol,2022,13:954992.
28 Dallavalasa S,Beeraka NM,Basavaraju CG,et al.The role of tumor associated macrophages(TAMs)in cancer progression,chemoresistance,angiogenesis and metastasis-current status[J].Curr Med Chem,2021,28(39):8203-8236.
29 Song J,Lin Z,Liu Q,et al.MiR-192-5p/RB1/NF-kappaBp65 signaling axis promotes IL-10 secretion during gastric cancer EMT to induce Treg cell differentiation in the tumour microenvironment[J].Clin Transl Med,2022,12(8):e992.
30 Wang Y,Ma H,Li Y,et al.MiR-192-5p-modified tumor-associated macrophages-derived exosome suppressed endometrial cancer progression through targeting IRAK1/NF-kappaB signaling[J].Reprod Sci,2022,29(2):436-447.
31 Han J,Won M,Kim JH,et al.Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective[J].Chem Soc Rev,2020,49(22):7856-7878.
32 Gu Y,Ji F,Liu N,et al.Loss of miR-192-5p initiates a hyperglycolysis and stemness positive feedback in hepatocellular carcinoma[J].J Exp Clin Cancer Res,2020,39(1):268.
33 Nishiyama A,Nakanishi M.Navigating the DNA methylation landscape of cancer[J].Trends Genet,2021,37(11):1012-1027.
34 Ni J,Tian W,Liang S,et al.Promoter methylation-mediated silencing of the MiR-192-5p promotes endometrial cancer progression by targeting ALX1[J].Int J Med Sci,2021,18(12):2510-2520.
35 Diener C,Keller A,Meese E.Emerging concepts of miRNA therapeutics:from cells to clinic[J].Trends Genet,2022,38(6):613-626.

[1]	程锦, 王玮. 维甲酸诱导蛋白在消化系统恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 502-506.
[2]	赵世博, 陈永峰, 黎惠怡, 符爱珍. Agrin参与恶性肿瘤发生发展的研究现状[J]. 实用肿瘤学杂志, 2023, 37(6): 507-512.
[3]	宋述铭, 李改琴, 张黎峰, 许凯, 毛雯靖, 张光辉. 新疆医科大学附属肿瘤医院2010—2020年恶性肿瘤住院患者流行病学分析[J]. 实用肿瘤学杂志, 2023, 37(5): 389-394.
[4]	文洪梅, 陈杨, 石青萍, 朱云芳, 任思颖, 唐娴, 邵英, 伍福仙, 李云飞. 2018年云南省肿瘤登记地区恶性肿瘤的发病与死亡分析[J]. 实用肿瘤学杂志, 2023, 37(4): 293-300.
[5]	周波蓉, 宋雅楠, 夏伟. 吡咯啉-5-羧酸还原酶-1在肿瘤中的作用及机制研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 267-271.
[6]	杨建华, 罗赛美, 龙欣甜, 李蔚, 杨璧榕, 余龙涛, 张腾, 文洪梅. 2017年云南省肿瘤登记地区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2023, 37(1): 6-10.
[7]	马骥雄, 马菊红, 周红, 鲁朝霞, 丁高恒, 刘玉琴. 2018年甘肃省白银市恶性肿瘤发病和死亡分析[J]. 实用肿瘤学杂志, 2023, 37(1): 11-16.
[8]	王钦, 刘军杰, 陆秀鑫, 吴雅菲, 张文皓. 基于铁死亡的纳米联合疗法在恶性肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 429-434.
[9]	何晓晴, 柯鹏, 张新友. BCL-2抑制剂在血液恶性肿瘤中的靶向治疗应用及作用机制[J]. 实用肿瘤学杂志, 2022, 36(5): 452-457.
[10]	李智慧, 李志高. 恩美曲妥珠单抗T-DM1在HER2阳性乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 477-482.
[11]	赵梓楠, 王国年. SOX4在消化系统恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 364-368.
[12]	吴芳芳, 郑桐森. 胆道恶性肿瘤辅助治疗的研究现状及展望[J]. 实用肿瘤学杂志, 2022, 36(2): 156-161.
[13]	唐菊, 尚利华. BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系[J]. 实用肿瘤学杂志, 2022, 36(2): 188-192.
[14]	王艳平, 邱琳, 武萌, 飒日娜. 2016年陕西省恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2022, 36(1): 1-6.
[15]	李娜, 邓茜, 蒋建军. NF-κB信号通路在恶性肿瘤化疗耐药中的作用[J]. 实用肿瘤学杂志, 2021, 35(6): 580-584.

miR-192-5p在恶性肿瘤中作用机制的研究进展

Research progress in the mechanism of miR-192-5p in malignant tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价